Jazz Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 64 to 72 Wednesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Jazz Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Jazz Pharmaceuticals is trying to complete a cup without handle with a 148.06 entry. See if it can clear the breakout price in volume at least 40% above average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 0%, compared to -36% in the prior report. Revenue increased from 0% to 2%.
Jazz Pharmaceuticals earns the No. 12 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Indivior are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
